nodes	percent_of_prediction	percent_of_DWPC	metapath
Fluocinolone Acetonide—PLA2G4A—Epirubicin—liver cancer	0.851	1	CbGbCtD
Fluocinolone Acetonide—Folliculitis—Sorafenib—liver cancer	0.00217	0.035	CcSEcCtD
Fluocinolone Acetonide—Secondary infection—Epirubicin—liver cancer	0.00171	0.0277	CcSEcCtD
Fluocinolone Acetonide—Rhinorrhoea—Sorafenib—liver cancer	0.00168	0.0272	CcSEcCtD
Fluocinolone Acetonide—Secondary infection—Doxorubicin—liver cancer	0.00158	0.0256	CcSEcCtD
Fluocinolone Acetonide—Rash papular—Epirubicin—liver cancer	0.00135	0.0218	CcSEcCtD
Fluocinolone Acetonide—Rash papular—Doxorubicin—liver cancer	0.00125	0.0202	CcSEcCtD
Fluocinolone Acetonide—Fungal skin infection—Epirubicin—liver cancer	0.0012	0.0195	CcSEcCtD
Fluocinolone Acetonide—Leukoderma—Epirubicin—liver cancer	0.00118	0.0191	CcSEcCtD
Fluocinolone Acetonide—Fungal skin infection—Doxorubicin—liver cancer	0.00111	0.018	CcSEcCtD
Fluocinolone Acetonide—Eczema—Sorafenib—liver cancer	0.0011	0.0178	CcSEcCtD
Fluocinolone Acetonide—Leukoderma—Doxorubicin—liver cancer	0.0011	0.0177	CcSEcCtD
Fluocinolone Acetonide—Pain in extremity—Sorafenib—liver cancer	0.000988	0.016	CcSEcCtD
Fluocinolone Acetonide—Nasopharyngitis—Sorafenib—liver cancer	0.000884	0.0143	CcSEcCtD
Fluocinolone Acetonide—Lacrimation—Epirubicin—liver cancer	0.000856	0.0138	CcSEcCtD
Fluocinolone Acetonide—Skin hyperpigmentation—Epirubicin—liver cancer	0.000846	0.0137	CcSEcCtD
Fluocinolone Acetonide—Folliculitis—Epirubicin—liver cancer	0.000801	0.0129	CcSEcCtD
Fluocinolone Acetonide—Lacrimation—Doxorubicin—liver cancer	0.000792	0.0128	CcSEcCtD
Fluocinolone Acetonide—Skin hyperpigmentation—Doxorubicin—liver cancer	0.000783	0.0127	CcSEcCtD
Fluocinolone Acetonide—Infestation NOS—Sorafenib—liver cancer	0.000762	0.0123	CcSEcCtD
Fluocinolone Acetonide—Infestation—Sorafenib—liver cancer	0.000762	0.0123	CcSEcCtD
Fluocinolone Acetonide—Folliculitis—Doxorubicin—liver cancer	0.000741	0.012	CcSEcCtD
Fluocinolone Acetonide—Connective tissue disorder—Sorafenib—liver cancer	0.000672	0.0109	CcSEcCtD
Fluocinolone Acetonide—Otitis media—Epirubicin—liver cancer	0.000646	0.0105	CcSEcCtD
Fluocinolone Acetonide—Abscess—Epirubicin—liver cancer	0.000636	0.0103	CcSEcCtD
Fluocinolone Acetonide—Rash pustular—Epirubicin—liver cancer	0.000631	0.0102	CcSEcCtD
Fluocinolone Acetonide—Mediastinal disorder—Sorafenib—liver cancer	0.000616	0.00997	CcSEcCtD
Fluocinolone Acetonide—Alopecia—Sorafenib—liver cancer	0.000604	0.00977	CcSEcCtD
Fluocinolone Acetonide—Mental disorder—Sorafenib—liver cancer	0.000599	0.00969	CcSEcCtD
Fluocinolone Acetonide—Otitis media—Doxorubicin—liver cancer	0.000598	0.00967	CcSEcCtD
Fluocinolone Acetonide—Malnutrition—Sorafenib—liver cancer	0.000595	0.00963	CcSEcCtD
Fluocinolone Acetonide—Erythema—Sorafenib—liver cancer	0.000595	0.00963	CcSEcCtD
Fluocinolone Acetonide—Abscess—Doxorubicin—liver cancer	0.000589	0.00952	CcSEcCtD
Fluocinolone Acetonide—Rash pustular—Doxorubicin—liver cancer	0.000584	0.00944	CcSEcCtD
Fluocinolone Acetonide—Dysgeusia—Sorafenib—liver cancer	0.000583	0.00943	CcSEcCtD
Fluocinolone Acetonide—Viral infection—Epirubicin—liver cancer	0.000557	0.00901	CcSEcCtD
Fluocinolone Acetonide—Herpes simplex—Epirubicin—liver cancer	0.000546	0.00883	CcSEcCtD
Fluocinolone Acetonide—Lacrimation increased—Epirubicin—liver cancer	0.000546	0.00883	CcSEcCtD
Fluocinolone Acetonide—Cough—Sorafenib—liver cancer	0.000519	0.0084	CcSEcCtD
Fluocinolone Acetonide—Viral infection—Doxorubicin—liver cancer	0.000516	0.00834	CcSEcCtD
Fluocinolone Acetonide—Neck pain—Epirubicin—liver cancer	0.000509	0.00824	CcSEcCtD
Fluocinolone Acetonide—Arthralgia—Sorafenib—liver cancer	0.000507	0.0082	CcSEcCtD
Fluocinolone Acetonide—Lacrimation increased—Doxorubicin—liver cancer	0.000505	0.00817	CcSEcCtD
Fluocinolone Acetonide—Herpes simplex—Doxorubicin—liver cancer	0.000505	0.00817	CcSEcCtD
Fluocinolone Acetonide—Dermatitis contact—Epirubicin—liver cancer	0.000497	0.00804	CcSEcCtD
Fluocinolone Acetonide—Infection—Sorafenib—liver cancer	0.000483	0.00781	CcSEcCtD
Fluocinolone Acetonide—Nervous system disorder—Sorafenib—liver cancer	0.000476	0.0077	CcSEcCtD
Fluocinolone Acetonide—Neck pain—Doxorubicin—liver cancer	0.000471	0.00762	CcSEcCtD
Fluocinolone Acetonide—Dry eye—Epirubicin—liver cancer	0.000465	0.00752	CcSEcCtD
Fluocinolone Acetonide—Dermatitis contact—Doxorubicin—liver cancer	0.00046	0.00744	CcSEcCtD
Fluocinolone Acetonide—Musculoskeletal discomfort—Sorafenib—liver cancer	0.000443	0.00716	CcSEcCtD
Fluocinolone Acetonide—Dry eye—Doxorubicin—liver cancer	0.00043	0.00696	CcSEcCtD
Fluocinolone Acetonide—Gastrointestinal disorder—Sorafenib—liver cancer	0.000419	0.00678	CcSEcCtD
Fluocinolone Acetonide—Pain—Sorafenib—liver cancer	0.000415	0.00672	CcSEcCtD
Fluocinolone Acetonide—Eczema—Epirubicin—liver cancer	0.000407	0.00657	CcSEcCtD
Fluocinolone Acetonide—Eye pain—Epirubicin—liver cancer	0.000405	0.00654	CcSEcCtD
Fluocinolone Acetonide—Body temperature increased—Sorafenib—liver cancer	0.000384	0.00621	CcSEcCtD
Fluocinolone Acetonide—Eczema—Doxorubicin—liver cancer	0.000376	0.00608	CcSEcCtD
Fluocinolone Acetonide—Eye pain—Doxorubicin—liver cancer	0.000374	0.00605	CcSEcCtD
Fluocinolone Acetonide—Hypoglycaemia—Epirubicin—liver cancer	0.000374	0.00605	CcSEcCtD
Fluocinolone Acetonide—Diplopia—Epirubicin—liver cancer	0.000365	0.00591	CcSEcCtD
Fluocinolone Acetonide—Pain in extremity—Epirubicin—liver cancer	0.000365	0.00591	CcSEcCtD
Fluocinolone Acetonide—Hypersensitivity—Sorafenib—liver cancer	0.000358	0.00579	CcSEcCtD
Fluocinolone Acetonide—Hypoglycaemia—Doxorubicin—liver cancer	0.000346	0.0056	CcSEcCtD
Fluocinolone Acetonide—Pruritus—Sorafenib—liver cancer	0.000344	0.00556	CcSEcCtD
Fluocinolone Acetonide—Diplopia—Doxorubicin—liver cancer	0.000338	0.00547	CcSEcCtD
Fluocinolone Acetonide—Pain in extremity—Doxorubicin—liver cancer	0.000338	0.00547	CcSEcCtD
Fluocinolone Acetonide—Diarrhoea—Sorafenib—liver cancer	0.000332	0.00538	CcSEcCtD
Fluocinolone Acetonide—Nasopharyngitis—Epirubicin—liver cancer	0.000327	0.00528	CcSEcCtD
Fluocinolone Acetonide—Dizziness—Sorafenib—liver cancer	0.000321	0.0052	CcSEcCtD
Fluocinolone Acetonide—Influenza—Epirubicin—liver cancer	0.000316	0.00511	CcSEcCtD
Fluocinolone Acetonide—Vomiting—Sorafenib—liver cancer	0.000309	0.005	CcSEcCtD
Fluocinolone Acetonide—Rash—Sorafenib—liver cancer	0.000306	0.00495	CcSEcCtD
Fluocinolone Acetonide—Dermatitis—Sorafenib—liver cancer	0.000306	0.00495	CcSEcCtD
Fluocinolone Acetonide—Headache—Sorafenib—liver cancer	0.000304	0.00492	CcSEcCtD
Fluocinolone Acetonide—Nasopharyngitis—Doxorubicin—liver cancer	0.000302	0.00489	CcSEcCtD
Fluocinolone Acetonide—Upper respiratory tract infection—Epirubicin—liver cancer	0.000293	0.00475	CcSEcCtD
Fluocinolone Acetonide—Influenza—Doxorubicin—liver cancer	0.000292	0.00472	CcSEcCtD
Fluocinolone Acetonide—Nausea—Sorafenib—liver cancer	0.000289	0.00467	CcSEcCtD
Fluocinolone Acetonide—Infestation NOS—Epirubicin—liver cancer	0.000282	0.00455	CcSEcCtD
Fluocinolone Acetonide—Infestation—Epirubicin—liver cancer	0.000282	0.00455	CcSEcCtD
Fluocinolone Acetonide—Upper respiratory tract infection—Doxorubicin—liver cancer	0.000272	0.00439	CcSEcCtD
Fluocinolone Acetonide—Sinusitis—Epirubicin—liver cancer	0.000264	0.00427	CcSEcCtD
Fluocinolone Acetonide—Infestation NOS—Doxorubicin—liver cancer	0.00026	0.00421	CcSEcCtD
Fluocinolone Acetonide—Infestation—Doxorubicin—liver cancer	0.00026	0.00421	CcSEcCtD
Fluocinolone Acetonide—Rhinitis—Epirubicin—liver cancer	0.000253	0.0041	CcSEcCtD
Fluocinolone Acetonide—Connective tissue disorder—Epirubicin—liver cancer	0.000248	0.00402	CcSEcCtD
Fluocinolone Acetonide—Sinusitis—Doxorubicin—liver cancer	0.000244	0.00395	CcSEcCtD
Fluocinolone Acetonide—Visual impairment—Epirubicin—liver cancer	0.000244	0.00394	CcSEcCtD
Fluocinolone Acetonide—Eye disorder—Epirubicin—liver cancer	0.000236	0.00382	CcSEcCtD
Fluocinolone Acetonide—Rhinitis—Doxorubicin—liver cancer	0.000234	0.00379	CcSEcCtD
Fluocinolone Acetonide—Connective tissue disorder—Doxorubicin—liver cancer	0.00023	0.00372	CcSEcCtD
Fluocinolone Acetonide—Mediastinal disorder—Epirubicin—liver cancer	0.000228	0.00368	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Regulation of Androgen receptor activity—JUN—liver cancer	0.000227	0.00258	CbGpPWpGaD
Fluocinolone Acetonide—Visual impairment—Doxorubicin—liver cancer	0.000225	0.00364	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Platelet activation, signaling and aggregation—PRKCE—liver cancer	0.000225	0.00256	CbGpPWpGaD
Fluocinolone Acetonide—Alopecia—Epirubicin—liver cancer	0.000223	0.00361	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—PDGFR-beta signaling pathway—BRAF—liver cancer	0.000221	0.00252	CbGpPWpGaD
Fluocinolone Acetonide—Mental disorder—Epirubicin—liver cancer	0.000221	0.00358	CcSEcCtD
Fluocinolone Acetonide—Erythema—Epirubicin—liver cancer	0.00022	0.00356	CcSEcCtD
Fluocinolone Acetonide—Malnutrition—Epirubicin—liver cancer	0.00022	0.00356	CcSEcCtD
Fluocinolone Acetonide—Eye disorder—Doxorubicin—liver cancer	0.000219	0.00353	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Phospholipid metabolism—PIK3CG—liver cancer	0.000218	0.00248	CbGpPWpGaD
Fluocinolone Acetonide—Dysgeusia—Epirubicin—liver cancer	0.000215	0.00348	CcSEcCtD
Fluocinolone Acetonide—NR3C1—AP-1 transcription factor network—CDKN2A—liver cancer	0.000215	0.00245	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Regulation of Androgen receptor activity—MAPK8—liver cancer	0.000215	0.00244	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Platelet activation, signaling and aggregation—IGF2—liver cancer	0.000213	0.00242	CbGpPWpGaD
Fluocinolone Acetonide—Back pain—Epirubicin—liver cancer	0.000213	0.00344	CcSEcCtD
Fluocinolone Acetonide—Mediastinal disorder—Doxorubicin—liver cancer	0.000211	0.00341	CcSEcCtD
Fluocinolone Acetonide—Vision blurred—Epirubicin—liver cancer	0.000207	0.00335	CcSEcCtD
Fluocinolone Acetonide—Alopecia—Doxorubicin—liver cancer	0.000207	0.00334	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—PCNA—liver cancer	0.000206	0.00235	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—SERPINE1—liver cancer	0.000205	0.00233	CbGpPWpGaD
Fluocinolone Acetonide—Mental disorder—Doxorubicin—liver cancer	0.000205	0.00331	CcSEcCtD
Fluocinolone Acetonide—Malnutrition—Doxorubicin—liver cancer	0.000204	0.00329	CcSEcCtD
Fluocinolone Acetonide—Erythema—Doxorubicin—liver cancer	0.000204	0.00329	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Platelet activation, signaling and aggregation—HGF—liver cancer	0.000201	0.00229	CbGpPWpGaD
Fluocinolone Acetonide—Dysgeusia—Doxorubicin—liver cancer	0.000199	0.00322	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Platelet activation, signaling and aggregation—CSF2—liver cancer	0.000199	0.00226	CbGpPWpGaD
Fluocinolone Acetonide—Vertigo—Epirubicin—liver cancer	0.000198	0.0032	CcSEcCtD
Fluocinolone Acetonide—Back pain—Doxorubicin—liver cancer	0.000197	0.00318	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Fc-epsilon receptor I signaling in mast cells—PIK3CA—liver cancer	0.000195	0.00222	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Generic Transcription Pathway—NR1H4—liver cancer	0.000192	0.00219	CbGpPWpGaD
Fluocinolone Acetonide—Cough—Epirubicin—liver cancer	0.000192	0.0031	CcSEcCtD
Fluocinolone Acetonide—Vision blurred—Doxorubicin—liver cancer	0.000192	0.0031	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Phospholipid metabolism—PIK3CD—liver cancer	0.000191	0.00218	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—AP-1 transcription factor network—CDKN1B—liver cancer	0.000191	0.00217	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Generic Transcription Pathway—NR1I3—liver cancer	0.000189	0.00215	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Adipogenesis—PPARA—liver cancer	0.000189	0.00215	CbGpPWpGaD
Fluocinolone Acetonide—Arthralgia—Epirubicin—liver cancer	0.000187	0.00303	CcSEcCtD
Fluocinolone Acetonide—NR3C1—AP-1 transcription factor network—IL2—liver cancer	0.000187	0.00212	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—PDGFR-beta signaling pathway—RAF1—liver cancer	0.000185	0.0021	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Endoderm Differentiation—CTNNB1—liver cancer	0.000184	0.0021	CbGpPWpGaD
Fluocinolone Acetonide—Vertigo—Doxorubicin—liver cancer	0.000183	0.00296	CcSEcCtD
Fluocinolone Acetonide—NR3C1—AP-1 transcription factor network—CCND1—liver cancer	0.000182	0.00207	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—AP-1 transcription factor network—JUN—liver cancer	0.000181	0.00207	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—MAPK14—liver cancer	0.000181	0.00206	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Fc-epsilon receptor I signaling in mast cells—HRAS—liver cancer	0.000181	0.00206	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—PDGFR-beta signaling pathway—PIK3CB—liver cancer	0.000181	0.00205	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—AP-1 transcription factor network—CTNNB1—liver cancer	0.00018	0.00205	CbGpPWpGaD
Fluocinolone Acetonide—Oedema—Epirubicin—liver cancer	0.00018	0.0029	CcSEcCtD
Fluocinolone Acetonide—Infection—Epirubicin—liver cancer	0.000178	0.00288	CcSEcCtD
Fluocinolone Acetonide—Cough—Doxorubicin—liver cancer	0.000178	0.00287	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—ESR1—liver cancer	0.000178	0.00202	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—AP-1 transcription factor network—MMP9—liver cancer	0.000177	0.00201	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Endothelins—HRAS—liver cancer	0.000176	0.002	CbGpPWpGaD
Fluocinolone Acetonide—Nervous system disorder—Epirubicin—liver cancer	0.000176	0.00285	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—SERPINA1—liver cancer	0.000176	0.002	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism of lipids and lipoproteins—CRABP1—liver cancer	0.000175	0.00199	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—UGDH—liver cancer	0.000174	0.00198	CbGpPWpGaD
Fluocinolone Acetonide—Arthralgia—Doxorubicin—liver cancer	0.000173	0.0028	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—CHN2—liver cancer	0.000171	0.00195	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—APC—liver cancer	0.000168	0.00191	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Phospholipid metabolism—PIK3CB—liver cancer	0.000167	0.0019	CbGpPWpGaD
Fluocinolone Acetonide—Oedema—Doxorubicin—liver cancer	0.000166	0.00269	CcSEcCtD
Fluocinolone Acetonide—Infection—Doxorubicin—liver cancer	0.000165	0.00267	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Glucocorticoid receptor regulatory network—IL2—liver cancer	0.000164	0.00187	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—EPT1—liver cancer	0.000164	0.00186	CbGpPWpGaD
Fluocinolone Acetonide—Musculoskeletal discomfort—Epirubicin—liver cancer	0.000164	0.00265	CcSEcCtD
Fluocinolone Acetonide—Nervous system disorder—Doxorubicin—liver cancer	0.000163	0.00263	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—JUN—liver cancer	0.000161	0.00184	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—PDGFR-beta signaling pathway—JUN—liver cancer	0.000161	0.00184	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Platelet activation, signaling and aggregation—MAPK14—liver cancer	0.000161	0.00183	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Glucocorticoid receptor regulatory network—JUN—liver cancer	0.00016	0.00182	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Fc-epsilon receptor I signaling in mast cells—AKT1—liver cancer	0.00016	0.00182	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—IFT88—liver cancer	0.000157	0.00178	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—CDKN1A—liver cancer	0.000157	0.00178	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Platelet activation, signaling and aggregation—F2—liver cancer	0.000156	0.00178	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Adipogenesis—PPARG—liver cancer	0.000156	0.00177	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Endothelins—AKT1—liver cancer	0.000156	0.00177	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—TAT—liver cancer	0.000155	0.00177	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Glucocorticoid receptor regulatory network—CDKN1A—liver cancer	0.000155	0.00176	CbGpPWpGaD
Fluocinolone Acetonide—Gastrointestinal disorder—Epirubicin—liver cancer	0.000155	0.00251	CcSEcCtD
Fluocinolone Acetonide—Pain—Epirubicin—liver cancer	0.000154	0.00248	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Metabolism of lipids and lipoproteins—HPGDS—liver cancer	0.000153	0.00174	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—PDGFR-beta signaling pathway—MAPK8—liver cancer	0.000153	0.00174	CbGpPWpGaD
Fluocinolone Acetonide—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.000151	0.00245	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Glucocorticoid receptor regulatory network—MAPK8—liver cancer	0.000151	0.00172	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—AGE/RAGE pathway—AKT1—liver cancer	0.00015	0.00171	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Platelet activation, signaling and aggregation—PIK3CG—liver cancer	0.000149	0.0017	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Endoderm Differentiation—TGFB1—liver cancer	0.000149	0.00169	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—FOXA2 and FOXA3 transcription factor networks—AKT1—liver cancer	0.000147	0.00167	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—AP-1 transcription factor network—MYC—liver cancer	0.000146	0.00166	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—AP-1 transcription factor network—TGFB1—liver cancer	0.000146	0.00166	CbGpPWpGaD
Fluocinolone Acetonide—Gastrointestinal disorder—Doxorubicin—liver cancer	0.000143	0.00232	CcSEcCtD
Fluocinolone Acetonide—Pain—Doxorubicin—liver cancer	0.000142	0.0023	CcSEcCtD
Fluocinolone Acetonide—Body temperature increased—Epirubicin—liver cancer	0.000142	0.0023	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Adipogenesis—SERPINE1—liver cancer	0.00014	0.0016	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—PDGFR-beta signaling pathway—STAT3—liver cancer	0.00014	0.00159	CbGpPWpGaD
Fluocinolone Acetonide—Hypersensitivity—Epirubicin—liver cancer	0.000132	0.00214	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—RAF1—liver cancer	0.000132	0.0015	CbGpPWpGaD
Fluocinolone Acetonide—Body temperature increased—Doxorubicin—liver cancer	0.000131	0.00212	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Platelet activation, signaling and aggregation—PIK3CD—liver cancer	0.000131	0.00149	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Generic Transcription Pathway—HNF4A—liver cancer	0.000131	0.00149	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—IFNA1—liver cancer	0.000131	0.00149	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Platelet activation, signaling and aggregation—SERPINE1—liver cancer	0.00013	0.00148	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—MYC—liver cancer	0.00013	0.00148	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—PDGFR-beta signaling pathway—MYC—liver cancer	0.00013	0.00148	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Platelet activation, signaling and aggregation—ALB—liver cancer	0.00013	0.00147	CbGpPWpGaD
Fluocinolone Acetonide—Pruritus—Epirubicin—liver cancer	0.000127	0.00205	CcSEcCtD
Fluocinolone Acetonide—Diarrhoea—Epirubicin—liver cancer	0.000123	0.00199	CcSEcCtD
Fluocinolone Acetonide—Hypersensitivity—Doxorubicin—liver cancer	0.000122	0.00198	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—CDKN1B—liver cancer	0.000121	0.00137	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—TRIO—liver cancer	0.00012	0.00137	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—AP-1 transcription factor network—TP53—liver cancer	0.00012	0.00136	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—PDGFR-beta signaling pathway—KRAS—liver cancer	0.00012	0.00136	CbGpPWpGaD
Fluocinolone Acetonide—Dizziness—Epirubicin—liver cancer	0.000119	0.00192	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—CASP3—liver cancer	0.000118	0.00135	CbGpPWpGaD
Fluocinolone Acetonide—Pruritus—Doxorubicin—liver cancer	0.000118	0.0019	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Platelet activation, signaling and aggregation—RAF1—liver cancer	0.000117	0.00133	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Gene Expression—EXOSC2—liver cancer	0.000116	0.00132	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—PRKCE—liver cancer	0.000116	0.00132	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—CCR4—liver cancer	0.000116	0.00131	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—CCND1—liver cancer	0.000115	0.00131	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—JUN—liver cancer	0.000115	0.00131	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Platelet activation, signaling and aggregation—PIK3CB—liver cancer	0.000114	0.0013	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism of lipids and lipoproteins—GGT1—liver cancer	0.000114	0.0013	CbGpPWpGaD
Fluocinolone Acetonide—Vomiting—Epirubicin—liver cancer	0.000114	0.00185	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—CTNNB1—liver cancer	0.000114	0.0013	CbGpPWpGaD
Fluocinolone Acetonide—Diarrhoea—Doxorubicin—liver cancer	0.000114	0.00184	CcSEcCtD
Fluocinolone Acetonide—Rash—Epirubicin—liver cancer	0.000113	0.00183	CcSEcCtD
Fluocinolone Acetonide—Dermatitis—Epirubicin—liver cancer	0.000113	0.00183	CcSEcCtD
Fluocinolone Acetonide—Headache—Epirubicin—liver cancer	0.000112	0.00182	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—CDKN1A—liver cancer	0.000111	0.00127	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—ABL1—liver cancer	0.00011	0.00125	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—PDGFR-beta signaling pathway—PIK3CA—liver cancer	0.00011	0.00125	CbGpPWpGaD
Fluocinolone Acetonide—Dizziness—Doxorubicin—liver cancer	0.00011	0.00178	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—IGF2—liver cancer	0.00011	0.00125	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Adipogenesis—CTNNB1—liver cancer	0.00011	0.00125	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—AP-1 transcription factor network—IL6—liver cancer	0.00011	0.00125	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—MAPK8—liver cancer	0.000109	0.00124	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Adipogenesis—CDKN1A—liver cancer	0.000107	0.00122	CbGpPWpGaD
Fluocinolone Acetonide—Nausea—Epirubicin—liver cancer	0.000107	0.00172	CcSEcCtD
Fluocinolone Acetonide—Vomiting—Doxorubicin—liver cancer	0.000106	0.00171	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Metabolism—GLUL—liver cancer	0.000106	0.0012	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—CPT1B—liver cancer	0.000106	0.0012	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Glucocorticoid receptor regulatory network—TP53—liver cancer	0.000106	0.0012	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Platelet activation, signaling and aggregation—IL2—liver cancer	0.000105	0.0012	CbGpPWpGaD
Fluocinolone Acetonide—Rash—Doxorubicin—liver cancer	0.000105	0.00169	CcSEcCtD
Fluocinolone Acetonide—Dermatitis—Doxorubicin—liver cancer	0.000105	0.00169	CcSEcCtD
Fluocinolone Acetonide—Headache—Doxorubicin—liver cancer	0.000104	0.00168	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—HGF—liver cancer	0.000104	0.00118	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—CSF2—liver cancer	0.000103	0.00117	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—PDGFR-beta signaling pathway—HRAS—liver cancer	0.000102	0.00116	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—NR1H4—liver cancer	0.000102	0.00116	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Phospholipid metabolism—PIK3CA—liver cancer	0.000102	0.00116	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—VEGFA—liver cancer	0.0001	0.00114	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—GSTA3—liver cancer	0.0001	0.00114	CbGpPWpGaD
Fluocinolone Acetonide—Nausea—Doxorubicin—liver cancer	9.87e-05	0.0016	CcSEcCtD
Fluocinolone Acetonide—NR3C1—SIDS Susceptibility Pathways—CASP3—liver cancer	9.84e-05	0.00112	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Glucocorticoid receptor regulatory network—IL6—liver cancer	9.66e-05	0.0011	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—SHC3—liver cancer	9.61e-05	0.00109	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Adipogenesis—STAT3—liver cancer	9.57e-05	0.00109	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—SIDS Susceptibility Pathways—JUN—liver cancer	9.56e-05	0.00109	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—SIDS Susceptibility Pathways—CTNNB1—liver cancer	9.49e-05	0.00108	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Gene Expression—NR1H4—liver cancer	9.27e-05	0.00105	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—MYC—liver cancer	9.24e-05	0.00105	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—TGFB1—liver cancer	9.21e-05	0.00105	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—GSTA4—liver cancer	9.16e-05	0.00104	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Gene Expression—NR1I3—liver cancer	9.11e-05	0.00104	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—AKT1—liver cancer	9e-05	0.00102	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism of lipids and lipoproteins—CYP1A1—liver cancer	8.95e-05	0.00102	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Platelet activation, signaling and aggregation—VEGFA—liver cancer	8.93e-05	0.00102	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—GSTA2—liver cancer	8.92e-05	0.00102	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Glucocorticoid receptor regulatory network—AKT1—liver cancer	8.91e-05	0.00101	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Adipogenesis—TGFB1—liver cancer	8.87e-05	0.00101	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—GSTA1—liver cancer	8.61e-05	0.000979	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—TNF—liver cancer	8.6e-05	0.000979	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—KRAS—liver cancer	8.53e-05	0.000971	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—NAT2—liver cancer	8.51e-05	0.000968	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—SIDS Susceptibility Pathways—VEGFA—liver cancer	8.35e-05	0.00095	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—MAPK14—liver cancer	8.3e-05	0.000945	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Adipogenesis—TNF—liver cancer	8.28e-05	0.000942	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Platelet activation, signaling and aggregation—TGFB1—liver cancer	8.2e-05	0.000933	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism of lipids and lipoproteins—PPARA—liver cancer	8.18e-05	0.000931	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—ALDOB—liver cancer	8.16e-05	0.000929	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—F2—liver cancer	8.05e-05	0.000915	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—PIK3CA—liver cancer	7.84e-05	0.000892	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—CRABP1—liver cancer	7.79e-05	0.000886	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—PIK3CG—liver cancer	7.7e-05	0.000876	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—TP53—liver cancer	7.59e-05	0.000863	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—FST—liver cancer	7.46e-05	0.000849	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—SIDS Susceptibility Pathways—TNF—liver cancer	7.16e-05	0.000814	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—TRIO—liver cancer	7.12e-05	0.00081	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	7.01e-05	0.000798	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Platelet activation, signaling and aggregation—PIK3CA—liver cancer	6.98e-05	0.000794	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Generic Transcription Pathway—PPARA—liver cancer	6.89e-05	0.000784	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—CCR4—liver cancer	6.82e-05	0.000776	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—HPGDS—liver cancer	6.8e-05	0.000774	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—PIK3CD—liver cancer	6.77e-05	0.00077	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism of lipids and lipoproteins—PPARG—liver cancer	6.76e-05	0.00077	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—SERPINE1—liver cancer	6.69e-05	0.000762	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Adipogenesis—IL6—liver cancer	6.68e-05	0.00076	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—ALB—liver cancer	6.68e-05	0.00076	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—PRKCE—liver cancer	6.65e-05	0.000757	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—AKT1—liver cancer	6.41e-05	0.000729	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Gene Expression—HNF4A—liver cancer	6.31e-05	0.000718	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Generic Transcription Pathway—ESR1—liver cancer	6.24e-05	0.00071	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	6.16e-05	0.000701	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism of lipids and lipoproteins—ALB—liver cancer	6.08e-05	0.000692	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—PSMD10—liver cancer	6.07e-05	0.00069	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—PSMA4—liver cancer	6.07e-05	0.00069	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—RAF1—liver cancer	6.04e-05	0.000688	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—GOT2—liver cancer	5.9e-05	0.000671	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—PIK3CB—liver cancer	5.9e-05	0.000671	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—CSF2—liver cancer	5.88e-05	0.000669	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—SIDS Susceptibility Pathways—IL6—liver cancer	5.78e-05	0.000657	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Platelet activation, signaling and aggregation—AKT1—liver cancer	5.7e-05	0.000649	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Generic Transcription Pathway—PPARG—liver cancer	5.69e-05	0.000648	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—CYP2E1—liver cancer	5.55e-05	0.000631	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Gene Expression—PSMA4—liver cancer	5.52e-05	0.000628	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Gene Expression—PSMD10—liver cancer	5.52e-05	0.000628	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—IL2—liver cancer	5.42e-05	0.000616	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—ADAM17—liver cancer	5.39e-05	0.000614	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	5.37e-05	0.000611	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—CYCS—liver cancer	5.19e-05	0.000591	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Generic Transcription Pathway—SERPINE1—liver cancer	5.13e-05	0.000584	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—GGT1—liver cancer	5.09e-05	0.000579	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—GOT1—liver cancer	5.09e-05	0.000579	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—PSMD10—liver cancer	5.07e-05	0.000577	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—PSMA4—liver cancer	5.07e-05	0.000577	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—F2—liver cancer	4.62e-05	0.000525	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—VEGFA—liver cancer	4.6e-05	0.000524	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—GSTP1—liver cancer	4.57e-05	0.000521	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—HMOX1—liver cancer	4.51e-05	0.000513	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—PIK3CG—liver cancer	4.42e-05	0.000503	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—TGFB1—liver cancer	4.23e-05	0.000481	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—GSTM1—liver cancer	4.2e-05	0.000478	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—CYP1A1—liver cancer	3.99e-05	0.000453	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—PRKCE—liver cancer	3.93e-05	0.000447	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—KRAS—liver cancer	3.91e-05	0.000445	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—PIK3CD—liver cancer	3.88e-05	0.000442	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Gene Expression—H2AFX—liver cancer	3.73e-05	0.000424	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—IGF2—liver cancer	3.72e-05	0.000424	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—MTHFR—liver cancer	3.72e-05	0.000423	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—PPARA—liver cancer	3.64e-05	0.000415	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—PIK3CA—liver cancer	3.6e-05	0.000409	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—TP53—liver cancer	3.48e-05	0.000396	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—CSF2—liver cancer	3.48e-05	0.000395	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—RAF1—liver cancer	3.47e-05	0.000395	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—H2AFX—liver cancer	3.43e-05	0.00039	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—PIK3CB—liver cancer	3.39e-05	0.000385	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—HRAS—liver cancer	3.33e-05	0.000379	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Gene Expression—PPARA—liver cancer	3.32e-05	0.000377	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	3.27e-05	0.000373	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Generic Transcription Pathway—MYC—liver cancer	3.25e-05	0.000369	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—PIK3CG—liver cancer	3.12e-05	0.000355	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—IL2—liver cancer	3.11e-05	0.000354	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—TERT—liver cancer	3.1e-05	0.000352	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Gene Expression—MAPK14—liver cancer	3.06e-05	0.000349	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—PPARG—liver cancer	3.01e-05	0.000343	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Gene Expression—ESR1—liver cancer	3e-05	0.000342	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—AKT1—liver cancer	2.94e-05	0.000334	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—KDR—liver cancer	2.83e-05	0.000322	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—MAPK14—liver cancer	2.81e-05	0.00032	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—ESR1—liver cancer	2.76e-05	0.000314	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—PIK3CD—liver cancer	2.74e-05	0.000312	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Gene Expression—PPARG—liver cancer	2.74e-05	0.000312	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—F2—liver cancer	2.73e-05	0.00031	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—ALB—liver cancer	2.71e-05	0.000308	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—APC—liver cancer	2.61e-05	0.000297	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—PIK3CG—liver cancer	2.61e-05	0.000297	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Gene Expression—SERPINE1—liver cancer	2.47e-05	0.000281	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—BRAF—liver cancer	2.45e-05	0.000279	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—PIK3CB—liver cancer	2.39e-05	0.000272	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—PIK3CD—liver cancer	2.29e-05	0.000261	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—SERPINE1—liver cancer	2.27e-05	0.000258	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—KRAS—liver cancer	2.25e-05	0.000256	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—PIK3CA—liver cancer	2.06e-05	0.000235	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—RAF1—liver cancer	2.05e-05	0.000233	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—MTOR—liver cancer	2e-05	0.000228	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—PIK3CB—liver cancer	2e-05	0.000228	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—HRAS—liver cancer	1.91e-05	0.000217	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—CDKN1B—liver cancer	1.88e-05	0.000214	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—CASP3—liver cancer	1.84e-05	0.000209	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—IL2—liver cancer	1.84e-05	0.000209	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—IL6—liver cancer	1.83e-05	0.000208	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—CCND1—liver cancer	1.79e-05	0.000204	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—JUN—liver cancer	1.79e-05	0.000203	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—CTNNB1—liver cancer	1.77e-05	0.000202	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—MMP9—liver cancer	1.74e-05	0.000198	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—CDKN1A—liver cancer	1.73e-05	0.000197	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—MAPK8—liver cancer	1.69e-05	0.000192	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—AKT1—liver cancer	1.69e-05	0.000192	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Gene Expression—MYC—liver cancer	1.56e-05	0.000178	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—VEGFA—liver cancer	1.56e-05	0.000178	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—STAT3—liver cancer	1.55e-05	0.000176	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—PIK3CA—liver cancer	1.46e-05	0.000166	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—MYC—liver cancer	1.44e-05	0.000163	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—TGFB1—liver cancer	1.43e-05	0.000163	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—KRAS—liver cancer	1.33e-05	0.000151	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—PIK3CA—liver cancer	1.22e-05	0.000139	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—AKT1—liver cancer	1.19e-05	0.000136	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—TP53—liver cancer	1.18e-05	0.000134	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—HRAS—liver cancer	1.13e-05	0.000128	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Gene Expression—AKT1—liver cancer	1.08e-05	0.000123	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—IL6—liver cancer	1.08e-05	0.000123	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—AKT1—liver cancer	9.96e-06	0.000113	CbGpPWpGaD
